Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models

Autologous patient-derived dendritic cells (DCs) modified ex vivo to present tumor-associated antigens (TAAs) are frequently used as cancer vaccines. However, apart from the stringent logistics in producing DCs on a patient basis, accumulating evidence indicate that ex vivo engineered DCs are poor i...

Descripción completa

Detalles Bibliográficos
Autores principales: Fotaki, Grammatiki, Jin, Chuan, Kerzeli, Iliana Kyriaki, Ramachandran, Mohanraj, Martikainen, Minttu-Maria, Karlsson-Parra, Alex, Yu, Di, Essand, Magnus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790347/
https://www.ncbi.nlm.nih.gov/pubmed/29399398
http://dx.doi.org/10.1080/2162402X.2017.1397250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790347/
https://www.ncbi.nlm.nih.gov/pubmed/29399398
http://dx.doi.org/10.1080/2162402X.2017.1397250

Ejemplares similares